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Objective The objective of this European multicenter
study was to report surgical outcomes of Fontan
takedown, Fontan conversion and heart transplantation
(HTX) for failing Fontan patients in terms of all-cause
mortality and (re-)HTX.
Methods A retrospective international study was
conducted by the European Congenital Heart Surgeons
Association among 22 member centres. Outcome of
surgery to address failing Fontan was collected in 225
patients among which were patients with Fontan
takedown (n=38; 17%), Fontan conversion (n=137;
61%) or HTX (n=50; 22%).
Results The most prevalent indication for failing Fontan
surgery was arrhythmia (43.6%), but indications differed
across the surgical groups (p<0.001). Fontan takedown
was mostly performed in the early postoperative phase
after Fontan completion, while Fontan conversion and
HTX were mainly treatment options for late failure. Early
(30 days) mortality was high for Fontan takedown
(ie, 26%). Median follow-up was 5.9 years (range
0–23.7 years). The combined end point mortality/HTX
was reached in 44.7% of the Fontan takedown patients,
in 26.3% of the Fontan conversion patients and in
34.0% of the HTX patients, respectively (log rank
p=0.08). Survival analysis showed no difference between
Fontan conversion and HTX (p=0.13), but their
ventricular function differed signiﬁcantly. In patients who
underwent Fontan conversion or HTX ventricular systolic
dysfunction appeared to be the strongest predictor of
mortality or (re-)HTX. Patients with valveless
atriopulmonary connection (APC) take more advantage
of Fontan conversion than patients with a valve-
containing APC (p=0.04).
Conclusions Takedown surgery for failing Fontan is
mostly performed in the early postoperative phase, with
a high risk of mortality. There is no difference in survival
after Fontan conversion or HTX.
INTRODUCTION
For patients with various forms of functional uni-
ventricular congenital heart defects (CHD), a direct
routing of the systemic return to the pulmonary
arteries, in the absence of a pulmonary cardiac
chamber, has been adopted as the usual surgical
option. Since its invention, independently by both
Fontan and Baudet1 and Kreutzer et al2 in 1971
and 1973 in France and Argentina, respectively, a
large series of surgical improvements and reﬁne-
ments have resulted in a better outcome for these
patients.3 Nowadays, it can be estimated that about
2.3:10 000 newborns with CHD are evaluated for
the staged Fontan pathway, and of these, the major-
ity reach adulthood.4
However, a growing body of evidence reveals
that life-threatening complications inevitably occur
from adolescence onwards. Therefore, the term
‘Failing Fontan’ has been introduced to refer to a
clinical situation with major rhythm disturbances
refractory to maximal medical therapy, thrombotic
events in the Fontan circuit, protein losing entero-
pathy (PLE), plastic bronchitis, chronic oedema and
ascites, cirrhosis and hepatic malignancy5 or ven-
tricular failure.6 7 The surgical solutions for
patients with failing Fontan have evolved over time.
Nowadays, three surgical options are embraced
worldwide: Fontan takedown,8 Fontan conversion
to an energetically more favourable connection (ie,
lateral tunnel (LT)9 or extracardiac conduit10) and
heart transplantation11 12 (HTX). These high-risk
procedures have been advocated based on institu-
tional experience with limited data and non-
uniform midterm results. The objective of this
international multicenter study is to perform a
comprehensive analysis of the midterm surgical
outcome for failing Fontan surgery, in order to
suggest an effective decision-making process for
this growing subset of critically ill patients.
METHODS
Patients
Patients who underwent Fontan surgery between
1971 and 31 December 2012 for the clinical syn-
drome of ‘Failing Fontan’ were eligible for inclu-
sion in the F2 study. Three surgical options were
taken into account: (1) Fontan takedown, (2)
Fontan conversion and (3) HTX. Fontan takedown
was deﬁned as a takedown of a completed Fontan
circulation to a superior cavopulmonary connection
(bidirectional Glenn (BDG)) or a systemic-to-
pulmonary arterial shunt (eg, Blalock–Taussig
shunt) or both. Fontan conversion included a con-
version from a traditional Fontan circulation (eg, an
atriopulmonary connection (APC) with or without
valve, or a Björk modiﬁcation) to a LT or extracar-
diac conduit (EC), and conversion from a LT to an
EC. Revisions (ie, major surgery to modify a
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suboptimal Fontan circuit without complete Fontan conversion)
were excluded from analysis. Patients were identiﬁed within par-
ticipating units of the European Congenital Heart Surgeons
Association, with the use of local registries searching for Fontan
patients or reviews of hospital patient charts. The University
Medical Center Groningen coordinated the study, collected the
data, maintained the database and performed all the data ana-
lyses. Review of medical records was approved by each local
committee on clinical investigation. Individual patients were not
identiﬁable, and the need for patient consent was waived.
Patient variables
The collected data on patient characteristics included primary
anatomical diagnosis, relevant cardiovascular comorbidity, surgi-
cal interventions before the initial Fontan procedure, important
prognostic patient variables previously described in Fontan
research, that is, New York Heart Association (NYHA) func-
tional class (FC)13 and cardiac function (ie, systolic ventricular
function14 and atrioventricular valve regurgitation15) and pre-
operative cardiac medication use. Furthermore, the indications
which led to failing Fontan surgery were classiﬁed as deteriorat-
ing FC, refractoriness of arrhythmia treatment, thrombus/
emboli, severe right atrial (RA) dilatation, hemodynamic import-
ant obstruction in Fontan circuit, pulmonary venous obstruc-
tion, PLE, atrioventricular valve surgery, Fontan bafﬂe leak or
subaortic stenosis. More than one indication was possible within
the same patient. Hemodynamic data (ie, RA pressure) from
latest heart catheterisation were available for 170 patients.
Finally, the following variables regarding failing Fontan surgery
were documented: aortic cross clamp time, cardiopulmonary
bypass time, duration of circulatory arrest, concomitant surgical
interventions and postoperative duration of mechanical ventila-
tion as well as hospital stay. Ventricular assist devices as a bridge
to transplant were documented.
Statistical analysis
Data were analysed with the use of SPSS V.20.0 for Windows.
Continuous data were reported as mean±SD or median (IQR)
and categorical data as number of patients (percentage of total,
within the surgical arm). The primary end point was all-cause
mortality or (re-)HTX. Secondary outcomes included early mor-
tality (within 30 days of failing Fontan surgery) and late mortal-
ity. The last follow-up ended at 1 January 2014. Patients’ data
were censored at the time of last contact. When appropriate, the
primary end point was analysed according to the
intention-to-treat principle. Thus, patients with a cross-over in
surgical strategy (eg, Fontan conversion and during follow-up
HTX) were analysed according to their initial intervention.
Baseline characteristics across the three groups were compared
using one-way analysis of variance or χ2 analyses, depending on
the variable of interest. For other comparisons, the Student’s t
test for continuous measures and the χ2 test (or Fisher’s exact
test) for categorical measures were used. Unadjusted survival
rates and survival curves were determined by Kaplan–Meier esti-
mates. The univariate and multivariate risk analyses of mortal-
ity/HTX were performed using time-dependent Cox
proportional hazards models. For these survival and risk ana-
lyses, patients with a Fontan takedown were excluded. A two-
sided p value <0.05 was considered to indicate statistical
signiﬁcance.
RESULTS
Two hundred twenty-ﬁve patients met the inclusion criteria
(ﬁgure 1). They were identiﬁed from 22 congenital heart
centres (range 1–40 patients/centre). Failing Fontan surgery
took place in the time era 1986–2012. See tables 1 and 2 for
the baseline characteristics. Patients were on average aged 5.9
±4.9 years when they either had Fontan completion or had a
one-stage Fontan procedure. In total, 136 patients (60.4%) had
some form of APC, whereas the remainder had a total cavopul-
monary connection (TCPC) (n=89; 39.6%).
In absolute counts, the most prevalent indication was arrhyth-
mia (98/225 patients=43.6%, table 3). For 78 patients (34.7%),
the decision for surgery was based on only one indication.
However, for the whole population, the combination of 2.0
±0.97 indications led to failing Fontan surgery. Arrhythmia and
RA dilatation were the main indications for Fontan conversion,
while deteriorating FC and PLE were the main indications for
HTX (p <0.001, ﬁgure 2).
Failing Fontan surgery
Fontan takedown was performed in 38 patients (17%), Fontan
conversion in 137 patients (61%, ie, 13% conversion to a
TCPC LT and 48% to a TCPC EC) and HTX in 50 patients
(22%). Two patients were successfully bridged to HTX by a
paracorporeal ventricular assist device. Of all patients treated
with Fontan conversion, 51.6% had concomitant rhythm
surgery (maze rhythm surgery). The cumulative occurrence of
surgical interventions for failing Fontan increased over time
(p=0.01, see online supplementary ﬁgure S1). Yet, the distribu-
tion across the surgical groups did not change during the
decades (p=0.19, see online supplementary ﬁgure S2).
The time interval between the initial Fontan procedure and
the failing Fontan surgery was signiﬁcantly shorter in the group
referred for a Fontan takedown procedure (0.6±1.9 years) com-
pared with patients who underwent HTX or Fontan conversion
(8.5±6.1 years and 15.2±7.0 years, respectively; p<0.001).
Comparison of the three groups also revealed statistical differ-
ences for the following variables: primary diagnosis, the pres-
ence of heterotaxy, previous BDG, type of initial Fontan
surgery, preoperative NYHA class, ventricular dysfunction, atrial
rhythm disturbances, RA pressure, age at failing Fontan surgery,
extracorporeal circulation time, ventilation time, intensive care
unit stay, hospital stay and medication use (tables 1 and 2).
Follow-up after Fontan takedown
During a mean follow up (FU) of 6.7±6.7 years (range 0–23.7
years), 15 patients (39.5%) died, of whom two-thirds (10/15
patients) in the ﬁrst 30 postoperative days (ie, early mortality
was 26.3%). After a mean period of 12.9±21.1 months, four
patients (10.5%) underwent HTX after Fontan takedown with
two patients alive at the end of follow-up. Two takedown
patients (5.3%) underwent subsequent TCPC LT operation after
a mean period of 34.1±14.1 months. A total of 17 patients
(44.7%) had reached the primary end point mortality/HTX at
the end of follow-up (see online supplementary ﬁgure S3).
Follow-up after Fontan conversion
During a mean FU of 7.7±5.7 years (range 0–24.7 years), a
total of 30 patients died (21.9%). Thirty-six patients (26.3%)
reached the combined end point mortality/HTX. Early mortality
was 15/137 (10.9%). In seven patients (5.2%), the Fontan con-
version was followed by HTX after a mean period of 3.3
±2.8 years. One of these seven patients died 19.1 years after
HTX. The primary end point mortality/HTX (n=36) occurred
during 1000 patient-years follow-up (event rate 3.6/100 patient-
years). Among the patients who survived Fontan conversion,
89% were in NYHA class I or II.
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Within the 130 patients with an APC, patients with valveless
APCs (n=89) had better outcomes after Fontan conversion
than those with a valve-containing APC (n=41; p=0.04,
ﬁgure 3). However, patients in the latter group were on
average 3.7±1.8 years older (p=0.04). Event-free survival after
Fontan conversion combined with MAZE rhythm surgery
(n=64; 51.6%) did not signiﬁcantly differ from Fontan con-
version without rhythm surgery (n=60; 48.4%, p=0.57).
Follow-up after HTX
During a mean FU of 5.7±5.4 years (range: 0–22.2 years), 17
patients (34%) died. No patients underwent retransplantation.
The mortality end point occurred during 287 patient-years
follow-up (event rate 5.9/100 patient-years). Early mortality was
14% and in-hospital mortality was 20%. Of all patients who
underwent failing Fontan surgery, HTX patients had the longest
extracorporeal circulation time (289±169 min) and hospital
Figure 1 Flowchart describing the
surgical treatment for patients with
failing Fontan (n=231). HTX, heart
transplantation; LT, lateral tunnel; EC,
extracardiac conduit.
Table 1 Baseline characteristics: demographics and medical history
Characteristic All (n=225) Conversion (n=137) Takedown (n=38) HTX (n=50) p Value
Male sex, N (%) 118 (52.4) 69 (50.4) 18 (47.4) 31 (62.0) 0.29
Diagnosis, N (%) <0.001
Tricuspid atresia 85 (37.8) 71 (51.8) 6 (15.8) 8 (16.0)
DILV 46 (20.4) 30 (21.9) 6 (15.8) 10 (20.0)
Unbalanced (A)VSD 21 (9.3) 5 (3.6) 10 (26.3) 6 (12.0)
HLHS 17 (7.6) 2 (1.5) 4 (10.5) 11 (22.0)
PA/IVS 17 (7.6) 11 (8.0) 2 (5.3) 4 (8.0)
Other 39 (17.3) 18 (13.1) 10 (26.3) 11 (22.0)
Heterotaxy, N (%) 38 (16.9) 15 (10.9) 13 (34.2) 10 (20.0) 0.003
Surgical history, N (%)
Pulmonary artery banding 47 (20.9) 25 (18.2) 11 (28.9) 11 (22.0) 0.35
Blalock–Taussig shunt 131 (58.2) 78 (56,9) 23 (60.5) 30 (60.0) 0.89
Bidirectional Glenn 72 (32.0) 13 (9.5) 26 (68.4) 33 (66.0) <0.001
Age at initial Fontan, years (±SD) 5.9 (4.9) 6.2 (4.8) 4.6 (2.9) 6.2 (6.1) 0.18
Type of initial Fontan surgery, N (%) <0.001
Björk modification 19 (8.4) 18 (13.1) 0 (0.0) 1 (2.0)
APC without valve 94 (41.8) 81 (59.1) 5 (13.2) 8 (16.0)
APC with valve 23 (10.2) 20 (14.6) 1 (2.6) 2 (4.0)
TCPC LT 45 (20.0) 18 (13.1) 12 (31.6) 15 (30.0)
TCPC EC 44 (19.6) 0 (0.0) 20 (52.6) 24 (48.0)
(A)VSD, (atrio)ventricular septum defect; APC, atriopulmonary connection; DILV, double inlet left ventricle; EC, extracardiac conduit; HLHS, hypoplastic left heart syndrome; HTX, heart
transplantation; LT, lateral tunnel; PA/IVS, pulmonary atresia with intact ventricular septum; TCPC, total cavopulmonary connection.
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stay (43.0±46.7 days). Among the patients who were discharged
from the hospital (n=43), 85% were in NYHA class I or II at
the end of follow-up.
Risk analyses for mortality/HTX after failing Fontan surgery
Mean follow-up after HTX or Fontan conversion was 6.9
±5.4 years. In only 15 patients, the follow-up duration exceeded
15 years and for that reason the unadjusted survival curve was
truncated at 15 years after failing Fontan surgery. Although the
survival curves diverge in favour of FC patients, event-free sur-
vival was not statistically different (p=0.13, ﬁgure 4).
Among the 187 patients with either a Fontan conversion or
HTX, the following characteristics were signiﬁcantly associated
with the primary end point: time interval between initial Fontan
surgery and failing Fontan surgery (ie, more events in patients
whose circulation start to fail within 10 years after initial
Fontan), NYHA class III/IV and ventricular dysfunction (table 4).
Multivariate analyses showed that patients with ventricular dys-
function have an increased risk of mortality/HTX (p=0.009).
Within the group of Fontan patients with an APC, no speciﬁc
treatment beneﬁt could be determined after 15 years follow-up
between FC and HTX (p=0.80).
DISCUSSION
This multicenter, European observational study of failing
Fontan patients is, to our knowledge, the largest in the world
permitting analysis to compare different surgical strategies for a
failing Fontan. We have shown that Fontan takedown has been
used as a surgical strategy in the early postoperative phase after
Fontan completion, whereas Fontan conversion or HTX were
the most important surgical options in the long run. In
Table 2 Preoperative and surgical variables (failing Fontan surgery)
Characteristic All (n=225) Conversion (n=137) Takedown (n=38) HTX (n=50) p Value
Age at failing Fontan surgery, years (±SD) 17.1 (10.3) 21.4 (8.9) 5.2 (3.2) 14.7 (9.4) <0.001
Time between Fontan completion and failing Fontan surgery, years (±SD) 11.2 (8.3) 15.2 (7.0) 0.6 (1.9) 8.5 (6.1) <0.001
NYHA class III/IV*, N (%) 112 (55.2) 45 (36.3) 22 (73.3) 45 (91.8) <0.001
≥Moderate AVV regurgitation, N (%) 55 (24.4) 29 (21.2) 10 (26.3) 16 (32.0) ns
Moderate/poor LV function, N (%) 115 (51.1) 58 (42.3) 14 (36.8) 43 (86.0) <0.001
Atrial rhythm disturbances, N (%) 112 (49.8) 91 (66.4) 4 (10.5) 17 (34.0) <0.001
RA pressure, mm Hg (±SD) 14.8 (4.3) 14.0 (4.2) 15.0 (4.2) 16.7 (4.0) 0.002
Medication use, N (%)
Aspirin 67 (29.8) 39 (28.5) 11 (28.9) 17 (34.0) <0.001
Coumadin 117 (52.0) 79 (57.7) 7 (18.4) 31 (62.0) <0.001
ACE-inhibitor 90 (40.0) 47 (34.3) 7 (18.4) 36 (72.0) <0.001
β-Blocker 43 (19.1) 35 (25.5) 0 (0.0) 8 (16.0) <0.001
Digoxin 56 (24.9) 32 (23.4) 8 (21.1) 16 (32.0) 0.004
Sotalol 29 (12.9) 25 (18.2) 1 (2.6) 3 (6.0) <0.001
Amiodarone 47 (20.9) 42 (30.7) 2 (5.3) 3 (6.0) <0.001
ECC time, min (±SD) 197 (119) 173 (89) 175 (86) 289 (169) <0.001
Ventilation time, days (±SD) 5.4 (11.7) 3.1 (4.7) 11.8 (22.9) 7.5 (12.3) 0.001
ICU stay, days (±SD) 12.9 (23.8) 8.0 (12.8) 23.8 (38.4) 18.6 (30.0) <0.001
Hospital stay, days (±SD) 28.9 (32.7) 21.8 (19.7) 37.6 (41.7) 43.0 (46.7) <0.001
*Available for 203 patients.
ACE, angiotension-converting enzyme; AVV, atrioventricular valve; ECC, extracorporeal circulation; HTX, heart transplantation; ICU, intensive care unit; LV, left ventricle; NYHA, New York
Heart Association; ns, not significant; RA, right atrial.
Table 3 Indications for failing Fontan surgery
Indication Number (%)
Arrhythmia 98 (43.6)
Deteriorating functional class 97 (43.1)
Extreme RA dilatation 87 (38.7)
Obstruction 47 (20.9)
Protein losing enteropathy 31 (13.8)
Thrombus 26 (11.6)
AVV regurgitation 18 (8.0)
Pulmonary vein stenosis 11 (4.9)
Cyanosis 12 (5.3)
Systemic obstruction 4 (1.8)
Baffle leak 4 (1.8)
AVV, atrioventricular valve; RA, right atrial.
Figure 2 Indications for failing Fontan surgery. More than one
indication is possible within the same patient. RA, right atrial; AVV,
atrioventricular valve; PV, pulmonary vein; PLE, protein losing
enteropathy; FC, functional class.
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comparison between the two latter strategies, no survival beneﬁt
could be identiﬁed, yet we have to realise that these groups are
selected for severity of ventricular dysfunction. Generally, the
ventricular function was much poorer in the HTX group as
compared with the conversion group. Furthermore, a valve-
containing conduit is a risk factor for Fontan conversion in
patients with APC with a failing Fontan circulation, the reason
of which is currently subject to speculation.
Although survival has improved markedly in the past
decades,3 Fontan patients are still at substantially increased risk
of late morbidity and death as compared with the normal popu-
lation.16 Presumably, the adult numbers of Fontan patients will
increase by over 60% in the next decade and the proportion in
NYHA FC III is expected to double.17 Unfortunately, a failing
Fontan circulation represents a particularly complicated scenario
for both patients and physicians.18 They are confronted with an
insidiously deteriorating clinical situation, while there are no
studies available that describe and compare treatment options.
Given the overall young age of this population with impaired
life expectancy, it is to be expected that a huge proportion of
these patients will be candidates for failing Fontan surgery. In
the current study, the complex nature of failing Fontan was con-
ﬁrmed since 65% of the failing Fontan patients had at least two
indications that led to the decision to operate.
The current study demonstrated that Fontan takedown has
primary been used as a bailout option in early Fontan failure,
considering the short interval between Fontan completion and
takedown surgery (ie, 7.2 months). This is in line with previous
small case series (n≤6), where Fontan takedown was accom-
plished in the early aftermath of Fontan completion.19 20 The
different characteristics of the Fontan takedown population
(‘early failing Fontan’) precludes a fair comparison with Fontan
conversion or HTX (‘late failing Fontan’) and therefore we
reported the outcome of this strategy separately. Our data
showed that mortality rates are very high (40% after a mean
follow-up of 6.7 years), especially in the ﬁrst 30 days after
Fontan takedown. Yet, the relative percentage of Fontan take-
downs steadily decreased over time. This probably points to
improved patient selection on the road towards Fontan comple-
tion. Whether Fontan takedown is a reasonable alternative for
HTX or Fontan conversion in late failing Fontan remains to be
elucidated.
Since the pioneering work of Mavroudis et al,21 Fontan con-
version to the more energy-efﬁcient extracardiac connection
with concomitant arrhythmia surgery is the standard for patients
with APC, especially those with atrial tachyarrhythmias. In their
own single-centre series including 111 Fontan conversions, an
early mortality rate of 0.9% was reported,22 but percentages up
to 13%23 are described. In our study, early mortality was 11%.
Recently, a study in 39 patients following Fontan conversion
reported 8 deaths (21%) after a mean follow-up of 6 years.
With a slightly longer mean follow-up (of 7.7 years), the current
study demonstrated a similar mortality rate of 21%.
We previously described the outcome after HTX in Fontan
patients (n=61), also including patients who initially were
treated with Fontan conversion or Fontan takedown.24 In the
current study, using an intention-to-treat analysis, we showed
that during a mean FU of 5.7 years 34% died. Early mortality
Figure 3 Kaplan–Meier plot showing the event-free survival for
patients with an atriopulmonary connection (APC)-type Fontan (n=130)
according to the presence or absence of a valve-containing conduit.
End points are mortality or heart transplantation. yrs, years.
Figure 4 Kaplan–Meier plot showing the event-free survival after
heart transplantation (HTX) (n=50) or Fontan conversion (n=137). Time
of follow-up is truncated at 15 years. End points are mortality or
(re-)HTX. FC, functional class; yrs, years.












26 (26.6) 0.049 ns
NYHA class III/IV 32 (35.6) 0.028 ns
Moderate/poor ventricular
function
37 (36.6) 0.004 2.52 (1.26 to 5.03) 0.009
HTX, heart transplantation; NYHA, New York Heart Association; ns, not significant.
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was high (20%), but this is in accordance with an actuarial sur-
vival after HTX of 80% at 6 months in a large cohort derived
from the Pediatric Heart Transplant Study database in the
USA.25
Perhaps the most compelling contribution of the current
study is the possibility to compare outcomes of Fontan conver-
sion and HTX. We now could provide evidence that survival
between HTX and Fontan conversion does not signiﬁcantly
differ. Furthermore, we found that poor systemic ventricular
function was a risk factor for death/HTX after failing Fontan
surgery. Possibly, ventricular dysfunction is associated with poor
general health status and high patient frailty in Fontan patients,
which may affect survival after surgery. Finally, it appeared that
valve-containing APCs are at increased risk for Fontan conver-
sion. For patients with APC, there was no speciﬁc treatment
beneﬁt for Fontan conversion or HTX, but this ﬁnding needs to
be interpreted cautiously due to the fact that within the 130
patients with an APC, 119 patients were treated with a Fontan
conversion, while only 11 patients were treated with HTX.
Nevertheless, these results may be of importance for future
treatment algorithms in patients with failing Fontan.
Our ﬁndings should be evaluated in the context of several
limitations. First of all, our study is limited by its observational
cohort design, which may complicate the interpretation of the
results, derived from four decades of data acquisition. Related
to this point, decision making for the different procedures was
based on the discretion of the treating physician(s) and not on
certain treatment algorithms. The best way to control for
treatment-selection bias is to conduct a randomised trial, but
given the relatively rare syndrome of failing Fontan, the set up
of such a trial is, unfortunately, an utopia. Hence, the three
pathways are not mutually exclusive and we have to realise that
the Fontan background is not identical for every patient (eg,
conversion is not an option for patients following TCPC EC).
Nevertheless, our dataset provides unique information on long-
term outcomes. Second, in our study we evaluated the three
most performed surgical treatments for failing Fontan. Despite
encouraging results of other surgical interventions in the last
years, for example, with ventricular assist devices,26 we analysed
these alternatives not systematically. Finally, some variables that
are known in clinical practice to have a profound effect on the
choice of failing Fontan surgery (eg, the presence of
systemic-to-pulmonary arterial or venovenous collateral ﬂow,
anthropomorphic characteristics of the patient and patient
frailty) were not available for this analysis.
In conclusion, the syndrome of failing Fontan is the result of
an inevitable and insidious attrition of the Fontan circulation.
Fontan takedown has been used as a surgical strategy for a
failing Fontan circulation in the early postoperative phase with
high risk for mortality. There is no difference in survival after
Fontan conversion or HTX. Hence, these groups are selected
for ventricular dysfunction. In general, a late failing Fontan
patient with a poor ventricular function is better off with an
HTX, while a patient with preserved ventricular function can
well be treated with conversion.
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Key messages
What is already known on this subject?
The Fontan circulation is subject to gradual attrition (‘Failing
Fontan’). No data are available to compare outcome of the
different surgical options to treat the failing Fontan circulation.
What might this study add?
Fontan takedown is generally performed at a short interval after
Fontan completion with a high risk of mortality. Fontan
conversion and heart transplantation (HTX) are the main
treatment options for late Fontan failure with no difference in
survival between the two techniques. Furthermore, we found
that poor systemic ventricular function was a risk factor for
death/HTX after failing Fontan surgery.
How might this impact on clinical practice?
These results may add to the decision-making process for this
growing subset of critically ill patients.
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